Sign in
Not yet recruitingPhase 4

Methadone Rapid Restart

Key facts

Who runs it
Pouya Azar
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
25 people, planned
Started
May 2026
Expected to end
Mar 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Methadone
Record updated
22 April 2026

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Age 19 years or older
  • Opioid use disorder (OUD) of any severity by DSM-5 TR Clinical Diagnostic criteria [American Psychiatric Association, 2022]
  • Previously 'stable' on methadone as per the below definitions:; Previous maintenance treatment with methadone for opioid use disorder at a stable dose for at least 5 consecutive days prior to discontinuing, with allowance for a maximum of 1 missed dose within that 5-day period; Participants who were being titrated on methadone for opioid use disorder prior to discontinuation. If participants were on the most recent dose for less than 5 days, they can be restarted on the prior dose providing they cumulatively received 5 consecutive doses (with a maximum of 1 missed dose in that period) between the two most recent dosages
  • Missed 4-8 doses of methadone in a row leading up to intake assessment
  • Participant able to provide baseline opiate use history as per opiate use screening questions in Appendix A. This must provide an estimate of opiate use prior to stopping methadone and change in use since stopping
  • Self-reported increased use of fentanyl since stopping methadone
  • No significant change in opiate withdrawal symptoms as compared to when on methadone, based on self-report and examination
  • Urine drug test (UDT) positive for fentanyl at screening or within 24 hours prior to re-initiating methadone
  • Participant wishes to continue methadone maintenance treatment
  • If applicable the participant must be willing to complete a urine pregnancy test to ensure they are not currently pregnant
  • Participants will require a baseline ECG that demonstrates a QTc < 500ms
  • For participants from VGH study site specifically:; must be admitted to either psychiatry or CTU, ideally with planned admission of at least 3 days; must agree if discharged prior to the completion of the 7 day follow up period, to either return to VGH Diamond Centre for follow up assessments on Days 1/3/7 (+/-2 days); must have access to a functioning cell phone to allow for the study team to contact them in case of discharge prior to completion of study follow up period
  • The participants must be willing and able to provide written informed consent for study participation

Who cannot take part

  • Self-reported Opioid overdose or naloxone administration since methadone discontinuation or during the 5 days prior to methadone discontinuation
  • Use of buprenorphine-naloxone (Suboxone®, Sublocade®, Butrans ®) within the previous 3 days (self-reported)
  • Self-reported New cardiac disease diagnosis since methadone discontinuation
  • Participants with a QTc interval >500 msec on the screening ECG
  • COWS score of 8 or more at the time of clinician assessment
  • Self-reported Intolerable side effects reported when taking methadone
  • Individuals who are pregnant (urine pregnancy test) or breast-feeding (self-reported)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The usual treatment for opioid use disorder (OUD) is opioid agonist therapy (OAT) with either methadone or buprenorphine. These treatments are well-established, reduce the risk of fatal overdoses, and are considered the standard approach. However, current methadone guidelines were developed when most people were using heroin, which is far less potent than today's unregulated/illicit fentanyl supply. As a result, people who use fentanyl often need higher doses to feel stable. Because methadone must be started at low doses and increased slowly, it can take weeks before someone reaches an effective dose. This process becomes even longer when doses are missed, since treatment often needs to be restarted at a lower level.

Read full original descriptionShow less

The Methadone Rapid Restart is a newer strategy designed to take ongoing fentanyl use into account. Early clinical experience and modelling suggest that many people who use fentanyl have high opioid tolerance and may be able to return to their previous stable methadone dose even after several missed days, without added safety risk. This approach has shown promise in small clinical settings, but it is not yet known whether it provides better outcomes than the standard methadone titration used today. This study will be testing whether this protocol to help rapidly restart people on Methadone is acceptable for patients and use the learning to guide a subsequent larger clinical trial.

The 2 groups in the trial

  • Methadone rapid restart for participants on methadone maintenance treatmentTreatment being tested

    Participants who have missed 4-8 doses of methadone, but were on maintenance treatment with methadone for opioid use disorder at a stable dose for at least 5 consecutive days prior to discontinuing, with allowance for a maximum of 1 missed dose within that 5-day period. These participants will be re-initiated on 100% of their most recent methadone dose.

    Treatment: Methadone

  • Methadone rapid restart for participants being titrated on methadoneTreatment being tested

    Participants who have missed 4-8 doses of methadone, but were being titrated on methadone prior to discontinuation such that they were on their most recent dosage for less than 5 days but received at least 5 consecutive days of methadone between the prior two dosages (with a maximum of 1 missed dose in that period) be. These participants will be restarted on the lower of their two most recent dosages.

    Treatment: Methadone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Methadone Rapid Restart Study
Record updated
22 April 2026